53 / 70
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 5, September/October 2019
AFRICA
295
13. Gebhard C, Kritikou EA, Tardif JC. Heart rate and atherosclerotic
plaque rupture: pathophysiological evidence and clinical perspectives.
Medicographia
2014;
36
: 63–72.
14. Roder F, Strotmann J, Fox H, Bitter T, Horstkotte D, Oldenburg O.
Interactions of sleep apnea, the autonomic nervous system, and its
impact on cardiac arrhythmias.
Curr Sleep Med Rep
2018;
4
: 160–169.
15. Smithwick RH, Thompson JE. Splanchnicectomy for essential hyperten-
sion; results in 1,266 cases.
J Am Med Assoc
1953;
152
(16): 1501–1504.
16. Heradien MJ, Augustyn J, Saaiman A, Brink PA. First reported cases:
renal denervation with second-generation multi-electrode catheter via
brachial and radial access.
Cardiovasc J Afr
2016;
2
7(1): 53–55.
17. Krum H, Schlaich M, Whitbourn R,
et al
. Catheter-based renal sympa-
thetic denervation for resistant hypertension: a multicentre safety and
proof-of-principle cohort study.
Lancet
2009;
373
(9671): 1275–1281.
18. Krum H, Schlaich MP, Sobotka PA,
et al
. Percutaneous renal denerva-
tion in patients with treatment-resistant hypertension: final 3-year report
of the Symplicity HTN-1 study.
Lancet
2014;
383
(9917): 622–629.
19. Symplicity HTN-2 Investigators, Esler MD, Krum H,
et al.
Renal
sympathetic denervation in patients with treatment-resistant hyperten-
sion (the Symplicity HTN-2 trial): a randomised controlled trial.
Lancet
2010;
376
(9756): 1903–1909.
20. Bhatt DL, Kandzari DE, O’Neill WW,
et al
. A controlled trial of renal
denervation for resistant hypertension.
N Engl J Med
2014;
370
(15):
1393–1401.
21. Messerli FH, Bangalore S. Renal denervation for resistant hypertension?
N Engl J Med
2014;
370
(15): 1454–1457.
22. Mahfoud F, Schmieder RE, Azizi M,
et al
. Proceedings from the 2nd
European Clinical Consensus Conference for device-based therapies
for hypertension: state of the art and considerations for the future.
Eur
Heart J
2017;
38
(44): 3272–3281.
23. Kandzari DE, Bhatt DL, Brar S,
et al
. Predictors of blood pressure
response in the SYMPLICITY HTN-3 trial.
Eur Heart J
2015;
36
(4):
219–227.
24. Flack JM, Bhatt DL, Kandzari DE,
et al
. An analysis of the blood pres-
sure and safety outcomes to renal denervation in African Americans and
non-African Americans in the SYMPLICITY HTN-3 trial.
J Am Soc
Hypertens
2015;
9
(10): 769–779.
25. Brewster LM, Seedat YK. Why do hypertensive patients of African
ancestry respond better to calcium blockers and diuretics than to ACE
inhibitors and
β
-adrenergic blockers? A systematic review.
BMC Med
2013;
11
: 141.
26. Ojji DB, Mayosi B, Francis V,
et al
.; CREOLE Study Investigators.
Comparison of dual therapies for lowering blood pressure in black
Africans.
N Engl J Med
2019 Mar 18. [Epub ahead of print].
27. Nieuwoudt S, Dickie KE, Coetsee C, Engelbrecht L, Terblanche E
(retracted article). Age- and education-related effects on cognitive
functioning in Colored South African women.
Neuropsychol Dev Cogn
B Aging Neuropsychol Cogn
2019;
28
: 1–17. [Epub ahead of print].
Retraction in Neuropsychol Dev Cogn B Aging Neuropsychol Cogn
2019 May 2.
28. Fengler K, Rommel KP, Hoellriegel R,
et al.
Pulse wave velocity predicts
response to renal denervation in isolated systolic hypertension.
J Am
Heart Assoc
2017;
6
(5) pii: e005879.
29. Sata Y, Hering D, Head GA,
et al
. Ambulatory arterial stiffness index as
a predictor of blood pressure response to renal denervation.
J Hypertens
2018;
36
(6): 1414–1422.
30. Ott C, Schmid A, Toennes SW, Ditting T, Veelken R, Uder M, Schmieder
RE. Central pulse pressure predicts BP reduction after renal denervation
in patients with treatment-resistant hypertension.
EuroIntervention
2015;
11
(1): 110–116.
31. Courand PY, Pereira H, Del Giudice C,
et al
. Abdominal aortic calcifica-
tions influences the systemic and renal hemodynamic response to renal
denervation in the DENERHTN (Renal Denervation for Hypertension)
Trial.
J Am Heart Assoc
2017;
6
(10) pii: e007062.
32. Ewen S, Ukena C, Linz D, Kindermann I,
et al.
Reduced effect of percu-
taneous renal denervation on blood pressure in patients with isolated
systolic hypertension.
Hypertension
2015;
65
(1): 193–199.
33. Berra E, Azizi M, Capron A,
et al
. Evaluation of adherence should
become an integral part of assessment of patients with apparently
treatment-resistant hypertension.
Hypertension
2016;
68
(2): 297–306.
34. McCambridge J, Witton J, Elbourne DR. Systematic review of the
Hawthorne effect: new concepts are needed to study research participa-
tion effects.
J Clin Epidemiol
2014;
67
(3): 267–277.
35. Pocock SJ, Bakris G, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to
the mean in SYMPLICITY HTN-3: implications for design and report-
ing of future trials.
J Am Coll Cardiol
2016;
68
(18): 2016–2025.
36. Sakakura K, Ladich E, Cheng Q,
et al
. Anatomic assessment of sympa-
thetic peri-arterial renal nerves in man.
J Am Coll Cardiol
2014;
64
:
635–643.
37. Mahfoud F, Pipenhagen CA, Boyce Moon L,
et al
. Comparison of
branch and distally focused main renal artery denervation using two
different radio-frequency systems in a porcine model.
Int J Cardiol
2017;
241
: 373–378.
38. Mahfoud F, Tunev S, Ewen S,
et al
. Impact of lesion placement on
efficacy and safety of catheter-based radiofrequency renal denervation.
J Am Coll Cardiol
2015;
66
(16): 1766–1775.
39. Townsend RR, Mahfoud F, Kandzari DE,
et al
. Catheter-based
renal denervation in patients with uncontrolled hypertension in the
absence of antihypertensive medications (SPYRAL HTN-OFF MED):
a randomised, sham-controlled, proof-of-concept trial.
Lancet
2017;
390
(10108): 2160–2170.
40. Kandzari DE, Böhm M, Mahfoud F,
et al
. Effect of renal denervation
on blood pressure in the presence of antihypertensive drugs: 6-month
efficacy and safety results from the SPYRAL HTN-ON MED proof-of-
concept randomised trial.
Lancet
2018;
391
(10137): 2346–2355.
41. Azizi M, Schmieder RE, Mahfoud F,
et al
. Endovascular ultrasound
renal denervation to treat hypertension (RADIANCE-HTN SOLO):
a multicentre, international, single-blind, randomised, sham-controlled
trial.
Lancet
2018;
391
(10137): 2335–2345.
42. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA,
Weissman JS. Primary medication non-adherence: analysis of 195,930
electronic prescriptions.
J Gen Intern Med
2010;
25
(4): 284–290.
43. Mokwatsi GG, Schutte AE, Mels CMC, Kruger R. Morning blood
pressure surge relates to autonomic neural activity in young non-dipping
adults: The African-PREDICT Study.
Heart Lung Circ
2018. pii: S1443-
9506(18)31829-8.
44. Seravalle G, Grassi G. Sympathetic nervous system, hypertension,
obesity and metabolic syndrome.
High Blood Press Cardiovasc Prev
2016;
23
(3): 175–179.
45. Mahfoud F, Bakris G, Bhatt DL,
et al
. Reduced blood pressure-lowering
effect of catheter-based renal denervation in patients with isolated
systolic hypertension: data from SYMPLICITY HTN-3 and the Global
SYMPLICITY Registry.
Eur Heart J
2017;
38
(2): 93–100.
46. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal
sympathetic-nerve ablation for uncontrolled hypertension.
N Engl J Med
2009;
361
(9): 932–934.
47. Chard M, Tabrizchi R. The role of pulmonary veins in atrial fibrillation:
a complex yet simple story.
Pharmacol Ther
2009;
124
(2): 207–218.
48. Kuck KH, Brugada J, Schlüter M,
et al
.; FIRE AND ICE Trial
Investigators. The FIRE AND ICE Trial: what we know, what we can